Directory
Xavier Matias-Guiu Guia

Xavier Matias-Guiu Guia

Degree: PhD

973 705 340
fjmatiasguiu.lleida.ics(ELIMINAR)@gencat.cat

ResearcherID: http://www.researcherid.com/rid/C-3039-2009

Publications

  • Matias-Guiu, X; Lerma, E; Prat, J

    Current topics in pathology of gynecologic tumors - a selective review

    INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY 6 121-134. .

    [doi:10.1177/106689699800600301]

  • Mato, E; Matias-Guiu, X; Chico, A; Webb, SM; Cabezas, R; Berna, L; De Leiva, A

    Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid carcinoma

    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM 83 2417-2420. .

    [doi:10.1210/jc.83.7.2417]

  • Albareda, M; Puig-Domingo, M; Wengrowicz, S; Soldevila, J; Matias-Guiu, X; Caballero, A; Chico, A; De Leiva, A

    Clinical forms of presentation and evolution of diffuse sclerosing variant of papillary carcinoma and insular variant of follicular carcinoma of the thyroid

    Thyroid 8 385-391. .

    [doi:10.1089/thy.1998.8.385]

  • Matias-Guiu, X; Machin, P; Pons, C; Lagarda, E; De Leiva, A; Prat, J

    Sustentacular cells occur frequently in the familial form of medullary thyroid carcinoma

    JOURNAL OF PATHOLOGY 184 420-423. .

    [doi:10.1002/(SICI)1096-9896(199804)184:4<420::AID-PATH1231>3.0.CO;2-R]

  • Cuatrecasas, M; Erill, N; Musulen, E; Costa, I; Matias-Guiu, X; Prat, J

    K-ras mutations in nonmucinous ovarian epithelial tumors - a molecular analysis and clinicopathologic study of 144 patients

    CANCER 82 1088-1095. .

    [doi:10.1002/(SICI)1097-0142(19980315)82:6<1088::AID-CNCR12>3.3.CO;2-A]

  • Chivite, A; Matias-Guiu, X; Pons, C; Algaba, F; Prat, J

    Inhibin a expression in adrenal neoplasms - a new immunohistochemical marker for adrenocortical tumors

    APPL IMMUNOHISTO M M 6 42-49. .

    [doi:10.1097/00022744-199803000-00008]

  • Matias-Guiu, X; Garrastazu, MT

    Composite phaeochromocytoma-ganglioneuroblastoma in a patient with multiple endocrine neoplasia type IIa

    Histopathology 32 281-282. .

  • Matias-Guiu, X; Garcia, A; Curell, R; Prat, J

    Renal cell carcinoma metastatic to the thyroid gland: a comparative molecular study between the primary and the metastatic tumor

    ENDOCRINE PATHOLOGY 9 255-260. .

    [doi:10.1007/BF02739966]

  • Matias-Guiu, J; Sempere, AP; Diaz-Marin, C; Beltran, I

    The contents of the neurological publications

    REVISTA DE NEUROLOGIA 25 2088-2088. .

  • MATIASGUIU, X; Lerma, E; Prat, J

    Clear cell tumors of the female genital tract

    SEMIN DIAGN PATHOL 14 233-239. .

  • Pujol, RM; MATIASGUIU, X; Miralles, J; Colomer, A; deMoragas, JM

    Multiple idiopathic mucosal neuromas: a minor form of multiple endocrine neoplasia type 2B or a new entity?

    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 37 349-352. .

    [doi:10.1016/S0190-9622(97)70025-2]

  • LaGuette, J; MATIASGUIU, X; Rosai, J

    Thyroid paraganglioma: a clinicopathologic and immunohistochemical study of three cases

    AMERICAN JOURNAL OF SURGICAL PATHOLOGY 21 748-753. .

    [doi:10.1097/00000478-199707000-00002]

Projects

  • Homologous recombination deficiency in high-grade endometrial cancers. Biomarkers and impact of intratumor heterogeneity.
  • EPH Receptor Signaling in Endometrial Cancer
  • Ajuts per a la contractació de personal investigador novell (FI)
  • Personalized Immunotherapy for Endometrial Cancer; Acronym: ExCITE (Endometrial Cancer Immunotherapy)
  • "Multi-Omics data for Cancer Research and the Development of New Diagnostics and Therapies"
  • EFFICACY: Nuevas estrategias para incrementar efectividad de los tratamientos con ABTL0812
  • Incorporación de nuevas areas temáticas y nuevos grupos al consorcio CIBER
  • Perfiles epigenéticos asociados a patrones de metastasis en cáncer de endometrio
  • CONTRACTES D'INCORPORACIO DE CIENTIFICS I TECNOLEGS: INCORPORACIO D'UNA DOCTORA PER A L'ACCIO ANTITUMORAL DELS CANNABINOIDES EN EL CARCINOMA D'ENDOMETRI
  • DISCOVERY, VALIDATION AND IMPLEMENTATION OF BIOMARKERS FOR PRECISION ONCOLOGY
  • Desarrollo de nuevas aproximaciones en el manejo individualizado de pacientes con cancer ginecológico (PREDICTGYN)
  • VALIDACION DE ANEXINA 2 COMO PREDICTOR DE RECIDIVA EN EL CANCER DE ENDOMETRIO. DISEÑO DE NUEVAS ESTRATEGIAS TERAPEUTICAS. ANXARECU